Literature DB >> 24846902

Factors associated with clinical deterioration shortly after PE.

Christopher Kabrhel1, Ikenna Okechukwu1, Praveen Hariharan1, James Kimo Takayesu1, Peter MacMahon2, Faris Haddad3, Yuchiao Chang4.   

Abstract

BACKGROUND: Several factors have been associated with mortality in the months after PE. Factors associated with short-term clinical deterioration or need for hospital-based intervention are less well known.
METHODS: We prospectively enrolled consecutive emergency department patients with PE and recorded clinical, biomarker and radiographic data. We assessed hospitalised patients daily to identify clinical deterioration or need for hospital-based intervention for 5 days after PE. We captured postdischarge events via 5-day and 30-day interviews. We used univariate and multivariable models to assess associations with clinical deterioration, severe clinical deterioration and 30-day all-cause mortality. We also assessed the test characteristics of three published clinical decision rules.
RESULTS: We enrolled 298 patients with PE: mean age 59 (SD±17) years; 152 (51%) male and 268 (90%) white race. 101 (34%) patients clinically deteriorated or required a hospital-based intervention within 5 days, and 197 (66%) did not. 27 (9%) patients suffered severe clinical deterioration and 12 died within 30 days. Factors independently associated with clinical deterioration were hypotension (p=0.001), hypoxia (p<0.001), coronary disease (p=0.004), residual deep vein thrombosis (p=0.006) and right heart strain on echocardiogram (p<0.001). In contrast, factors associated with 30-day all-cause mortality were active malignancy (p<0.001) and congestive heart failure (p=0.009). The sensitivity of clinical decision rules was moderate (39-80%) for 5-day clinical deterioration but higher (67-100%) for 30-day mortality.
CONCLUSIONS: Most patients do not clinically deteriorate after PE diagnosis. Several factors are associated with short-term clinical deterioration, but these factors differ from those associated with 30-day mortality. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24846902     DOI: 10.1136/thoraxjnl-2013-204762

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  15 in total

Review 1.  Findings From 12-lead Electrocardiography That Predict Circulatory Shock From Pulmonary Embolism: Systematic Review and Meta-analysis.

Authors:  Jacob D Shopp; Lauren K Stewart; Thomas W Emmett; Jeffrey A Kline
Journal:  Acad Emerg Med       Date:  2015-09-22       Impact factor: 3.451

2.  Metabolomic analysis of 92 pulmonary embolism patients from a nested case-control study identifies metabolites associated with adverse clinical outcomes.

Authors:  O A Zeleznik; E M Poole; S Lindstrom; P Kraft; A Van Hylckama Vlieg; J A Lasky-Su; L B Harrington; K Hagan; J Kim; B A Parry; N Giordano; C Kabrhel
Journal:  J Thromb Haemost       Date:  2018-01-30       Impact factor: 5.824

3.  Impact of relative contraindications to home management in emergency department patients with low-risk pulmonary embolism.

Authors:  David R Vinson; Carrieann E Drenten; Jie Huang; J Eileen Morley; Megan L Anderson; Mary E Reed; Daniel K Nishijima; Vincent Liu
Journal:  Ann Am Thorac Soc       Date:  2015-05

4.  Septal bowing and pulmonary artery diameter on computed tomography pulmonary angiography are associated with short-term outcomes in patients with acute pulmonary embolism.

Authors:  Mads Dam Lyhne; Jacob Gammelgaard Schultz; Peter J MacMahon; Faris Haddad; Mannudeep Kalra; David Mai-King Tso; Alona Muzikansky; Michael H Lev; Christopher Kabrhel
Journal:  Emerg Radiol       Date:  2019-08-02

5.  Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study.

Authors:  Gregory J Fermann; Petra M G Erkens; Martin H Prins; Philip S Wells; Ákos F Pap; Anthonie W A Lensing
Journal:  Acad Emerg Med       Date:  2015-02-25       Impact factor: 3.451

Review 6.  Ultrasound Assisted Catheter-Directed Thrombolysis of Acute Pulmonary Embolism: A Review of Current Literature.

Authors:  Muhammad A Mangi; Hiba Rehman; Vikas Bansal; Omer Zuberi
Journal:  Cureus       Date:  2017-07-19

Review 7.  Reducing the hospital burden associated with the treatment of pulmonary embolism.

Authors:  W Frank Peacock; Adam J Singer
Journal:  J Thromb Haemost       Date:  2019-04-01       Impact factor: 5.824

8.  Outpatient treatment of low-risk venous thromboembolism with monotherapy oral anticoagulation: patient quality of life outcomes and clinician acceptance.

Authors:  Jeffrey A Kline; Zachary P Kahler; Daren M Beam
Journal:  Patient Prefer Adherence       Date:  2016-04-15       Impact factor: 2.711

9.  Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding.

Authors:  Jeffrey A Kline; David Jimenez; D Mark Courtney; Juliana Ianus; Lynn Cao; Anthonie W A Lensing; Martin H Prins; Philip S Wells
Journal:  Acad Emerg Med       Date:  2016-01-14       Impact factor: 3.451

Review 10.  Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients.

Authors:  Daniel Corrigan; Christiana Prucnal; Christopher Kabrhel
Journal:  Clin Exp Emerg Med       Date:  2016-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.